Related Experiment Video
Updated: Feb 22, 2026

IP-FCM: Immunoprecipitation Detected by Flow Cytometry
Published on: December 2, 2010
The complex patent situation regarding antibody Fc engineering
1Michalski Hüttermann & Partner Patentanwälte mbB, Düsseldorf, Germany.
Abstract:
Fc domain engineering enables precise modulation of antibody effector functions, serum half-life, conjugation sites, and chain pairing. However, the associated patent landscape is highly complex, shaped by inconsistent mutation numbering, overlapping claims, and variable patent term extensions. This article outlines key technological strategies-ranging from Fcγ receptor and FcRn affinity modulation to antibody-drug conjugate optimization-and illustrates common intellectual property pitfalls with representative patents. Practical approaches to freedom-to-operate assessment are discussed, including reliance on expired technologies, licensing options, and layered composition-of-matter protection. Regulatory safe harbour provisions and their implications for antibody R&D are also reviewed, providing a practical guide for navigating Fc engineering patents.
Related Concept Videos
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Drug Products: Biologics, Biosimilars and Interchangeables

